In part 2 of our MASLD series, Sven Francque outlines that resmetirom is now approved in F2-F3 fibrosis in parts of Europe, semaglutide has produced positive phase 3 data in MASH, and the guideline is being updated.
Tune in now:
š https://bit.ly/44R97K3
